Orforglipron (LY-3502970)
Oral Small-Molecule GLP-1 Receptor Agonist · Weight Loss & Diabetes
Overview
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
91% achieved near-normal blood sugar levels versus 42% with placebo.
Mechanism
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
Research areas
- First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
- Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
- ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
- ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
- Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
- 91% achieved near-normal blood sugar levels versus 42% with placebo.
- ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
- Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
Research notes
- Diarrhea (more prevalent than with injectable GLP-1s)
- Nausea (typically improves after first month)
- Appetite reduction
- Severe or persistent abdominal pain radiating to back (potential pancreatitis)
- Neck lumps, hoarseness, difficulty swallowing, or neck swelling
- Severe nausea/vomiting preventing adequate nutrition or hydration
- Signs of severe hypoglycemia (confusion, sweating, rapid heartbeat)
- Suicidal thoughts, severe depression, or significant mood changes
- Vision changes or persistent eye pain
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy and breastfeeding
Pharmacokinetics
- Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
FAQs
How does orforglipron compare to semaglutide for weight loss?
Orforglipron achieved 12.4% weight loss vs semaglutide's 15-20% in trials, but orforglipron is an oral tablet while semaglutide requires weekly injections. For many people, the convenience of taking a daily pill outweighs slightly lower weight loss numbers. It's still in Phase 3 trials (not yet FDA-approved), while semaglutide is established.
Why does orforglipron cause more diarrhea than other GLP-1s?
The file specifically notes that diarrhea is more prevalent with orforglipron than with injectable GLP-1s. This is likely due to its oral bioavailability and how the small molecule formulation affects the GI tract differently than peptide injections. Diarrhea typically improves after the first month as your body adapts.
Can I take orforglipron with food, or does it need an empty stomach?
Orforglipron can be taken with or without food and at any time of day, according to the protocols. This flexibility is a key advantage over some other GLP-1 formulations. You don't need to plan around meals for administration.
Is orforglipron safe if I have a family history of thyroid cancer?
No. Orforglipron is contraindicated if you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Like other GLP-1 agonists, there's a theoretical risk of thyroid C-cell tumors. Discuss your family history thoroughly with your healthcare provider before starting.